Announced Thu, 9 Jul · 20:07 IST
Bacil Pharma Board Approves Rights Issue Worth up to 50 Crore
Fund Raising View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.2%1-day move
₹38.36
prior close
₹39.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9———-2.2-2.2-3.9-3.8-4.8-14.3————
Up moveDown movePending
AI summary
Bacil Pharma board approved a Rights Issue of equity shares worth up to ₹50 Crore. Authorised share capital will rise by ₹45 Crore to ₹65 Crore total. Two Independent Directors resigned. A Rights Issue Committee has been formed and intermediaries (Purva Sharegistry, Axis Bank, Acuite Ratings) appointed. Issue price, entitlement ratio, and record date are yet to be decided.
Likely market impact
Rights Issue may dilute existing shareholders. Use of funds is not disclosed, so watch for further details on purpose and pricing.